Blue Jet Healthcare Ltd
Incorporated in 1968, Blue Jet Healthcare (earlier called Jet Chemicals Pvt Ltd) is a pharmaceutical and healthcare ingredient & intermediate company and the first manufacturer of saccharin and its salts (artificial sweeteners) in India.[1]
- Market Cap ₹ 12,385 Cr.
- Current Price ₹ 714
- High / Low ₹ 1,028 / 464
- Stock P/E 87.9
- Book Value ₹
- Dividend Yield 0.17 %
- ROCE 57.3 %
- ROE 52.1 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | |
|---|---|---|
| 538 | 499 | |
| 324 | 293 | |
| Operating Profit | 214 | 206 |
| OPM % | 40% | 41% |
| 6 | 4 | |
| Interest | 7 | 5 |
| Depreciation | 18 | 20 |
| Profit before tax | 194 | 185 |
| Tax % | 25% | 26% |
| 145 | 136 | |
| EPS in Rs | 24,141.67 | 1,396.49 |
| Dividend Payout % | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -3% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 42% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 52% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | |
|---|---|---|
| Equity Capital | 0.60 | 10 |
| Reserves | 201 | 330 |
| 79 | 53 | |
| 95 | 143 | |
| Total Liabilities | 375 | 536 |
| 107 | 139 | |
| CWIP | 2 | 3 |
| Investments | 34 | 37 |
| 232 | 358 | |
| Total Assets | 375 | 536 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | |
|---|---|---|
| 123 | 129 | |
| -45 | -51 | |
| -72 | -28 | |
| Net Cash Flow | 5 | 51 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | |
|---|---|---|
| Debtor Days | 80 | 105 |
| Inventory Days | 120 | 253 |
| Days Payable | 90 | 128 |
| Cash Conversion Cycle | 110 | 231 |
| Working Capital Days | 51 | 88 |
| ROCE % | 57% |
Documents
Announcements
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 3h
-
Announcement Under Regulation 30 (LODR)-Offer For Sale
2d - Akshay Arora sold 10,734,529 shares (6.19%) on Sep 10-11, 2025; promoter stake falls to 79.81%.
-
Updates on Notice of Offer for Sale of Shares by Promoter
10 Sep - With reference to the earlier announcement dated September 09, 2025 regarding Notice of Offer for Sale of Shares by Promoter & Floor Price, Akshay Bansarilal …
- Notice of Offer for Sale of Shares by Promoter & Floor Price 9 Sep
- Announcement under Regulation 30 (LODR)-Newspaper Publication 3 Sep
Concalls
-
Jul 2025Transcript PPT REC
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Oct 2024TranscriptNotesPPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT
Product Portfolio
A) Contrast Media Intermediates (67.7% of FY24 revenue)[1]
Contrast media are chemical agents that enhance imaging clarity for diagnostic purposes, making tissues more visible under X-rays, CT scans, MRIs, and ultrasounds. The company supplies critical starting and advanced intermediates to the world's top contrast media manufacturers.